Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
canakinumab 180 MG Injection [Ilaris]
Known as:
CANAKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Ilaris]
, ILARIS 180 MG Injection
National Institutes of Health
Create Alert
Related topics
Related topics
7 relations
Histidine
Injection
Polysorbate 80
Sucrose
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Canakinumab (ILARIS®) in cryopyrin-associated periodic syndrome (CAPS)patients below 2 years of age: Review of four cases and literature.
Dhilleswara Rao Vana
2017
Corpus ID: 4147550
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic…
Expand
Review
2015
Review
2015
Canakinumab: A Review of Its Use in the Management of Systemic Juvenile Idiopathic Arthritis
Sheridan M. Hoy
BioDrugs
2015
Corpus ID: 18230885
Subcutaneous canakinumab (Ilaris®) is a human monoclonal anti-human interleukin (IL)-1β antibody of the immunoglobulin G1…
Expand
2014
2014
Опыт применения ингибитора интерлейкина 1β канакинумаба у больного с хронической тофусной подагрой
Array С. Елисеев
,
Array Желябин
,
Array Г. Барскова
,
A. Насонов
RSP
2014
Corpus ID: 59925804
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with…
Expand
Review
2013
Review
2013
Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares
K. Lyseng-Williamson
BioDrugs
2013
Corpus ID: 18307953
Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a…
Expand
Review
2013
Review
2013
FRI0430 Comparative effectiveness and health economic evaluation of systemic anti-inflammatory therapies for acute GOUT flares
K. Reiter
,
E. Krishnan
,
J. Goldhaber-Fiebert
2013
Corpus ID: 75255163
Background There have been few published comparisons of various treatment options for acute gout flares that incorporate costs…
Expand
2013
2013
THU0392 Beta-confident-registry: Efficacy and safety of canakinumab in cryopyrin associated periodic syndrome - 18 month follow-up
J. Kuemmerle-Deschner
,
P. Hawkins
,
H. Hoffman
,
T. van der Poll
,
U. Walker
,
H. Tilson
2013
Corpus ID: 75476966
Background Canakinumab (CAN, Ilaris®), a fully human anti-IL-1β monoclonal antibody, selectively inhibits IL-1β and has been…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE